Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

MELAS Clinical Trial

Official title:
A Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Individuals With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

Status Terminated

Clinical Trial Summary

This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.

Clinical Trial Description

IW-6463 tablets will be orally administered once-daily (QD) for up to 29 days ;

Study Design

Related Conditions & MeSH terms

Acidosis
Acidosis, Lactic
MELAS
MELAS Syndrome
Mitochondrial Encephalomyopathies

Clinical Trial Details

NCT number	NCT04475549
Study type	Interventional
Source	Tisento Therapeutics
Contact
Status	Terminated
Phase	Phase 2
Start date	November 13, 2020
Completion date	January 23, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06051448` - Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).	Phase 1/Phase 2
Completed	`NCT02909400` - The KHENERGY Study	Phase 2
Completed	`NCT02544217` - A Dose-escalating Clinical Trial With KH176	Phase 1
Enrolling by invitation	`NCT01803906` - Tissue Sample Study for Mitochondrial Disorders
Active, not recruiting	`NCT04846036` - The KHENERGYC Study	Phase 2
Completed	`NCT03432871` - Nicotinamide Riboside and Mitochondrial Biogenesis	N/A